MedTrace Logo

Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study

NCT00443105 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2007-03-05

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Tacrolimus 0.03% ointment (Protopic)

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • David Zadok, MD · Assaf Harofeh Medical Center, Tel Aviv University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00443105 on ClinicalTrials.gov